The Sugar Shuffle: Abbott and Google Join Forces on AI-Powered Monitoring

The recent partnership between health care company Abbott and Google Health has sparked interest in the potential benefits of AI-powered glucose monitoring for non-diabetics. While the collaboration promises to provide insights into metabolic health, it’s essential to separate hype from reality.

One concern is the lack of clear evidence supporting the use of continuous glucose monitors (CGMs) for individuals without diabetes. Research suggests that tracking blood sugar spikes might lead to better dietary choices, but the benefits are far from certain. In fact, an overemphasis on keeping readings low could potentially lead to poor eating habits. This trend is worrying, particularly given the growing popularity of CGMs among non-diabetics.

The Lingo device, which Abbott has partnered with Google Health to integrate into their ecosystem, is designed for adults who don’t use insulin. However, research supporting the benefits of such close tracking for this population is scarce. The Johns Hopkins Bloomberg School of Public Health published an article earlier this year stating that the health benefits are “pretty hazy.”

The partnership between Abbott and Google could lead to groundbreaking insights into metabolic health, particularly in areas where data is currently lacking. By integrating continuous glucose, wearable, laboratory, and survey data, the companies aim to uncover connections between activity, sleep, wellbeing, and metabolic health. This could ultimately inform more personalized guidance that supports healthier day-to-day decisions.

However, it’s equally plausible that the alliance will yield findings that prioritize driving sales over improving public health. The partnership comes with a lucrative revenue stream: users of the Lingo device can share their data with the Google Health Coach, which offers AI-driven recommendations based on an individual’s information. This creates a clear conflict of interest, where the primary goal is to monetize user data rather than genuinely advance our understanding of metabolic health.

The responsibility of tech giants like Google and Abbott in promoting health-related technologies raises questions about their role in shaping public health policy. While their intentions may be good, the potential consequences of such close tracking are far-reaching and complex. Dr. Idrees Mughal, a medical doctor with experience using CGMs, noted that even trained professionals struggle to interpret results without additional context.

The partnership between Abbott and Google is an example of how the pursuit of innovation can sometimes overshadow the need for evidence-based research. It’s essential that we proceed with caution, recognizing both the potential benefits and risks associated with AI-powered glucose monitoring for non-diabetics. As users, policymakers, and healthcare professionals, it’s crucial to engage in an informed discussion about what this means for our collective understanding of metabolic health.

The Abbott-Google alliance is a case study in the complexities of modern healthcare. By examining the potential consequences of such close tracking and questioning the motivations behind its promotion, we can work towards developing more effective solutions that truly benefit public health rather than simply generating revenue.